A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination With Backbone Treatments for Subjects With Multiple Myeloma

Trial Profile

A Phase I Multi-Cohort Trial of Pembrolizumab (MK-3475) in Combination With Backbone Treatments for Subjects With Multiple Myeloma

Suspended
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Pembrolizumab (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms KEYNOTE-023
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 05 Jul 2017 According to a Merck AG media release, status changed from recruiting to suspended.
    • 05 Jul 2017 According to a Merck & Co. media release, this trial has been placed on partial clinical hold by the US FDA due to safety concerns observed in KEYNOTE-183 and KEYNOTE-185 trials. All patients enrolled in this trial will discontinue investigational treatment with pembrolizumab.
    • 25 Jun 2017 Safety, efficacy and biomarker results presented at the 22nd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top